IL1B and benign prostatic hyperplasia: demonstrated the immunohistochemical presence of IL-1β in 75% of normal prostate samples, in 42.86% of BPH samples, and in 31.25% of PCa samples with low Gleason grade, while no positive immunoreactions were observed in PCa samples with high Gleason grade, suggesting that a progressive loss of IL-1β is associated with more aggressive pathologies [132].